How ‘Longtermism’ Is Helping the Tech Elite Justify Ruining the World
By Rohitha Naraharisetty,
The Swaddle
| 09. 05. 2022
"transhuman" by new 1lluminati is licensed under CC BY 2.0.
“It’s as if they want to build a car that goes fast enough to escape from its own exhaust.”
These words were the takeaway from a meeting that Douglas Rushkoff, who describes himself as a “Marxist media theorist,” had with five extremely powerful people in tech who were looking to survive the impending climate catastrophe. Rushkoff’s account of this in Survival of the Richest reveals something sinister: that righ-ranking elites in tech genuinely know what’s coming — but rather than stopping it, they’re planning on saving themselves from it in the form of underground luxury bunkers and armed guards comprised of Navy SEALs.
The people who are almost directly responsible for the world’s biggest problems today — the climate crisis, eroding institutions of democracy, and the sale of people’s own attention for profit — don’t find themselves to be accountable. Not only that, accountability, or even fixing today’s problems, isn’t even a desirable goal for them. At least not, according to ‘longtermism’ — the philosophy undergirding much...
Related Articles
By Liyan Qi and Jonathan Cheng, The Wall Street Journal | 03.26.2025
photo via Wikimedia Commons licensed under CC by 3.0
Chinese scientist He Jiankui set off global outrage and landed in prison after he skirted ethical guidelines and claimed he had produced genetically modified babies designed to resist HIV infection.
Now, the self-styled ...
By Carsten T. Charlesworth, Henry T. Greely, and Hiromitsu Nakauchi, MIT Technology Review | 03.25.2025
Why do we hear about medical breakthroughs in mice, but rarely see them translate into cures for human disease? Why do so few drugs that enter clinical trials receive regulatory approval? And why is the waiting list for organ transplantation...
By Anna Louie Sussman, The New York Times | 03.25.2025
On June 24, 2022, the same day the Supreme Court issued its decision in Dobbs v. Jackson Women’s Health Organization, I received a call from the fertility clinic where I’d been undergoing in vitro fertilization, informing me that seven of...
By Michael Gibney, PharmaVoice | 03.20.2025
The death this week of a teenager receiving Sarepta Therapeutics’ gene therapy Elevidys for Duchenne muscular dystrophy is a tragic reminder of the stakes involved in cutting-edge biotech innovation.
While gene therapies like Sarepta’s offer an opportunity to treat and...